Evolving medical therapies for ulcerative colitis.

被引：12
作者：
Cohen R.D. [1 ]
机构：
[1] Department of Medicine, University of Chicago Medical Center, Section of Gastroenterology, 5841 South Maryland Avenue, Chicago, 60637, IL
来源：
Current Gastroenterology Reports | 2002年 / 4卷 / 6期
关键词：
Ulcerative Colitis; Infliximab; Budesonide; Mesalazine; Ulcerative Colitis Patient;
D O I：
10.1007/s11894-002-0026-y
中图分类号：
学科分类号：
摘要：
Therapies for patients with ulcerative colitis have, until recently, been limited in scope and efficacy. New formulations of mesalamine and corticosteroids have challenged the older therapies with respect to both efficacy and safety. The application of 6-mercaptopurine and azathioprine for steroid-refractory disease and maintenance of remission has resulted in studies of other candidate immunomodulatory agents. Biologic therapies targeting tumor necrosis factor, adhesion molecules, or other cytokines are under intense scrutiny as potential disease-altering agents that may even replace currently available products. Other approaches, including such wide-ranging products as heparin, nicotine, and probiotics, suggest that control of ulcerative colitis may require an individualized approach for each patient.
引用
收藏
页码：497 / 505
页数：8
相关论文
共 243 条
[1]  
Levine DS(2002)A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis Am J Gastroenterol 97 1398-1407
[2]  
Riff DS(2002)A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis Aliment Pharmacol Ther 16 61-68
[3]  
Pruitt R(2002)A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis Aliment Pharmacol Ther 16 69-77
[4]  
Green JR(2001)Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses Gut 49 783-789
[5]  
Mansfield JC(2001)Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs Gut 48 571-577
[6]  
Gibson JA(2000)Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis Aliment Pharmacol Ther 14 155-161
[7]  
Mansfield JC(2000)A metaanalysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis Am J Gastroenterol 95 1263-1276
[8]  
Giaffer MH(2000)Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study Aliment Pharmacol Ther 14 1191-1198
[9]  
Cann PA(2000)Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis Am J Gastroenterol 95 1749-1754
[10]  
Kruis W(1999) ( Ital J Gastroenterol Hepatol 31 677-684
12345678910